Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

Chimeric antigen receptors (CARs) In CAR T-cell therapies, T cells are taken from the patient's blood and are changed in the lab by adding a gene for a receptor (called a chimeric antigen receptor or ...

Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.

Experimental treatment could offer a safer, cheaper alternative to CAR-T-cell therapies for disorders such as lupus.

Legend Biotech Corp. ADR advanced stock charts by Barron's. View LEGN historical stock data and compare to other stocks, and exchanges.

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the tumor site, enabling them to target ...